pc3

Abacavir (Ziagen) is a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.

Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16/30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.

Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.

Abacavir sulfate (Ziagen) , a nucleoside analogue, effectively utilize its antiviral activity

RHPS4 (RHPS 4 methosulfate) is a potent inhibitor of Telomerase at submicromolar.

Podophyllotoxinone, a natural compound found in Dysosma versipellis, shows inhibitory activity against L1210 leukemia and KB cells in vitro.

Periplocymarin is a cardiac glycoside with anticancer potential isolated from Periploca sepium and Periploca graeca.

trans-C75 ((±)-C75) is an enantiomer of C75, which is an inhibitor of fatty-acid synthase (FASN).

C75 is a fatty acid synthase (FASN) inhibitor (IC50 = 35 μM in PC3 cells) with cell permeability and the ability to activate CPT1A. This compound possesses antitumor activity and is commonly used in cancer-related experimental research.

PC 18:0-20:0 (PC3 aa C38:0) (Standard) is a reference standard of PC 18:0-20:0 (PC3 aa C38:0) intended for quantitative analysis, quality control, and related biochemical research applications.

TRPC3 agonist-1 (compound 4n) is a selective competitive activator of the TRPC3 channel, binding specifically to the L2 site of hTRPC3.

VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors.

VPC32179 is a bioactive chemical.

TRPC3/6-IN-1 is a highly potent and selective inhibitor that blocks the activity of canonical transient receptor channels TRPC3 and TRPC6, showing significant potency against human isoforms hTRPC3 and hTRPC6 with IC50 values of 1260 nM and 500 nM, respectively. This compound is valuable for research on chronic models of heart failure [1].

TRPC3/6-IN-2 is a potent inhibitor of TRPC3 and TRPC6, with IC50 values of 16 nM and 29.8 nM, respectively [1].

Anti-GPC3 Antibody (YP7) is a chimeric mouse IgG1, κ antibody that specifically targets human GPC3. The recommended isotype control for Anti-GPC3 Antibody (YP7) is Mouse IgG1 kappa, Isotype Control.

GPC3 targeting peptide 1 is a synthetic peptide ligand that binds to glypican-3 (GPC3) with a high affinity dissociation constant (Kd) of 0.23 nM. GPC3 targeting peptide 1 serves as a precise molecular probe for detecting and targeting GPC3-expressing tumor cells, particularly in hepatocellular carcinoma research, facilitating targeted imaging and therapeutic applications.

GPC3 targeting peptide 1 TFA binds with GPC3, exhibiting a dissociation constant (Kd) of 0.23 nM.

DOTA-GPC3 targeting peptide 2 is a type of RDC peptide composed of DOTA and GPC3 targeting peptide 2. It can be labeled with radioactive elements. The GPC3 targeting peptide 2 (Seq30) binds to GPC3 with a dissociation constant (Kd) of 0.3 nM.

Phytochelatin 3 (PC3) is a glutathione-derived peptide and heavy metal detoxifier/chelator consisting of 3 units of glu-cys.

Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent, inducing cell apoptosis and inhibiting the growth of TNBC cancer cell lines (IC50s: 10 nM - 20 nM).

CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.

SNS-314 Mesylate (SNS-314) is an effective and specific Aurora A/B/C inhibitor (IC50: 9/31/3 nM). It is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2.

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971(CCG203971) causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.